Research prototype · seeking design partners

AI copilot
for the
molecular lab.

PathCopilot drafts guideline-grade interpretations from raw sequencing data — variant tiers, risk classification, therapy signals, every claim cited. The pathologist reviews, edits, and signs. Decision support, never the decision.

Explore HemeCopilot

Built on LLMs · Human-in-the-loop by design

HEM-2026-0142 · AMLIntermediate · ELN 2022
AI draft · 4 variants · 14 citationsconf 84%
INPM1p.W288fs38%
IFLT3ITDmidostaurin42%
IIDNMT3Ap.R882H45%
IIITET2p.Q1261*CHIP?11%
Classic NPM1 + FLT3-ITD + DNMT3A triad. Midostaurin indicated during induction (RATIFY). Low-VAF TET2 may represent clonal hematopoiesis — flag for pathologist review.

Illustrative — AI-drafted, pathologist-reviewed

Guideline-boundAMP/ASCO/CAP 2017ELN 2022 · 2024IPSS-MWHO 2022ICC 2022NCCNOncoKB · ClinVar · CIViC

The platform

One trustworthy substrate. Many specialties.

Every PathCopilot module is built on the same spine — an evidence-bound drafting engine, a versioned knowledge base, a continuous eval harness, and a complete audit trail from AI call to sign-out.

01 · Human-in-the-loop

The pathologist signs

AI produces a draft. A board-certified pathologist reviews every field, edits inline, and signs out. The model is never the decision-maker.

02 · Evidence-bound

No claim without a citation

Every classification traces to KB evidence or a named guideline. Insufficient evidence becomes a VUS with an explicit uncertainty note — not a guess.

03 · Audit-complete

Everything is logged

Each AI call, edit, amendment, and sign-out is recorded with model, prompt version, and tokens — ready for CAP/CLIA documentation.

Modules
Unlocked per lab
● Live

HemeCopilot

Variant interpretation for hemato-oncology. AML, MDS, MPN, ALL, CLL — ELN 2022, IPSS-M, WHO 2022.

AMLMDSMPNALLCLLOthers
Explore the product →
Coming soon

HistoCopilot

Histopathology diagnosis support. Structured reporting, pattern recognition, and guideline-based classification.

Structured reportsSynoptic
Contact the PathCopilot team to unlock
Coming soon

GeneticsCopilot

Germline interpretation & hereditary cancer risk. ACMG/AMP classification support.

ACMG/AMPHereditary risk
Contact the PathCopilot team to unlock

How it works

From sequencing output to a signed report.

01


Ingest the case

Import a VCF or enter variants manually with karyotype and clinical context. Variants are enriched against OncoKB, ClinVar, and CIViC before drafting.

02


LLM drafts

A structured draft is generated — per-variant tiers, risk classification, co-mutation context, therapy signals, germline flags, and citations — in seconds.

03


Review & sign out

Edit any field inline. Every change is versioned. Sign out with a typed signature and a complete, exportable audit trail.

04


AI Assistant

Ask the HemeCopilot assistant anything about variant classification, treatment options, or disease biology. Each response draws from the same evidence base as full interpretations — credits managed by your lab admin.

Evidence & rigor

Built with an AI chatbot for clinical queries — held to the same evidence standard as a signed report.

The interpretation prompt is product code — versioned in git, changed through review, and run against an expert-validated eval set on every change. A score regression blocks the merge.

See how HemeCopilot is validated →
20
expert-validated eval cases
≥0.80
aggregate score to ship
100%
AI calls audit-logged
5
hemato-onc disease contexts

Become a design partner

Bring PathCopilot into your lab's workflow.

We're working directly with molecular pathologists to validate the prototype. Tell us how your lab signs out cases and we'll shape the product around it.

Explore HemeCopilot